Comparative Pharmacology
Head-to-head clinical analysis: ALOXI versus ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALOXI versus ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE.
ALOXI vs ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective serotonin 5-HT3 receptor antagonist; blocks serotonin binding at 5-HT3 receptors in the chemoreceptor trigger zone and gastrointestinal tract, preventing nausea and vomiting.
Selective 5-HT3 receptor antagonist; blocks serotonin at vagal afferent terminals in the gastrointestinal tract and in the central nervous system chemoreceptor trigger zone.
0.25 mg intravenously over 30 seconds, administered 30 minutes before chemotherapy on day 1 of each cycle; not to be repeated within 7 days.
8 mg orally or intravenously every 8 hours, or 32 mg intravenously as a single dose 30 minutes before chemotherapy.
None Documented
None Documented
Terminal elimination half-life is approximately 40 hours (range 33–45 hours) in adults, allowing once-daily dosing for prevention of chemotherapy-induced nausea and vomiting.
Clinical Note
moderateRaloxifene + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Raloxifene."
Clinical Note
moderateRaloxifene + Erythromycin
"The metabolism of Erythromycin can be decreased when combined with Raloxifene."
Clinical Note
moderateRaloxifene + Cyclosporine
"The metabolism of Cyclosporine can be decreased when combined with Raloxifene."
Clinical Note
moderateRaloxifene + Fluconazole
Terminal elimination half-life is approximately 3–6 hours in adults, but may be prolonged to 5–7 hours in elderly patients and up to 20 hours in patients with severe hepatic impairment (Child-Pugh score ≥10).
Renal (approximately 50% unchanged drug), biliary/fecal (approximately 35% as metabolites). Total clearance is 160 ± 38 mL/min.
Approximately 95% of the dose is metabolized, with less than 5% excreted unchanged in urine. Renal excretion is the primary route for metabolites (about 50% of total elimination). Fecal excretion accounts for approximately 25% of the dose.
Category C
Category A/B
5-HT3 Antagonist
5-HT3 Antagonist
"The metabolism of Fluconazole can be decreased when combined with Raloxifene."